Progesterone to Prevent Miscarriage in Women with Early Pregnancy Bleeding: The PRISM Trial
Source: View publication →
In this large, multicenter, double-blind, placebo-controlled trial, vaginal micronised progesterone did not significantly increase the rate of live births among all women presenting with early pregnancy bleeding, although a subgroup analysis suggested benefit for women with a history of recurrent miscarriage.
Key Findings
Study Design
Study Limitations
Clinical Significance
While progesterone is not indicated for all women presenting with threatened miscarriage, the findings support its use in women with early pregnancy bleeding who have a history of previous miscarriage, leading to updated clinical guidelines (e.g., NICE) in certain jurisdictions.
Historical Context
Before the PRISM trial, smaller studies and meta-analyses provided conflicting data regarding the efficacy of progesterone in treating threatened miscarriage, necessitating a large, robustly designed trial to clarify its role in clinical practice.
Guided Discussion
High-yield insights from every perspective
What is the physiological role of progesterone in early pregnancy maintenance, and how does the 'progesterone block' theory justify its use in threatened miscarriage?
Key Response
Progesterone is essential for decidualization of the endometrium and maintaining uterine quiescence by inhibiting myometrial contractions (the 'progesterone block'). The trial investigates whether exogenous progesterone can compensate for potential luteal phase deficiency or stabilize the pregnancy in the face of early bleeding.
Based on the PRISM trial results, which specific subgroup of patients presenting with threatened miscarriage should be prioritized for vaginal micronised progesterone, and what is the magnitude of the benefit?
Key Response
While the primary outcome was non-significant for the overall population, the subgroup analysis showed a significant increase in live birth rates for women with a history of recurrent miscarriage (3 or more previous losses), with a live birth rate of 72% in the progesterone group versus 57% in the placebo group (Rate Ratio 1.28).
Discuss the clinical implications of the 'biological gradient' observed in the PRISM trial regarding the number of previous miscarriages and its impact on the Number Needed to Treat (NNT).
Key Response
The trial demonstrated a clear trend: as the number of previous miscarriages increased, the benefit of progesterone treatment became more pronounced. For women with no previous losses, the NNT was essentially infinite; for those with 1-2 losses, it was roughly 25; and for those with 3 or more losses, the NNT was 7, indicating highly effective targeted therapy.
How does the PRISM trial resolve the historical 'harmless but useless' perception of progesterone in early pregnancy, and how should this change our counseling of patients with their first-ever episode of bleeding?
Key Response
PRISM provides high-quality evidence that routine use for all-comers is not indicated, allowing clinicians to avoid unnecessary treatment in low-risk patients. For those with their first bleeding episode and no prior losses, clinicians can confidently counsel that progesterone does not significantly improve outcomes, shifting the focus to expectant management and reassurance.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the use of a 2% minimum clinically important difference (MCID) in the power calculation of the PRISM trial and discuss how this influence may have led to a 'near-significant' p-value for the primary outcome.
Key Response
The study was powered to detect a 5% difference (75% vs 80%), requiring a large sample size (n=4153). The actual observed difference was 3% (75% vs 72%, p=0.08). A researcher must evaluate if the trial was slightly underpowered for a smaller but potentially still clinically relevant effect, or if the p-value accurately reflects a lack of universal therapeutic efficacy.
Given that the primary outcome of the PRISM trial was statistically non-significant (p=0.08), what features of the trial's design and subgroup analysis justify its publication in a high-impact journal like NEJM?
Key Response
The trial's exceptional rigor (multi-center, double-blind, large N), the pre-specification of the miscarriage-history subgroup, and the clear public health importance of the negative primary finding (preventing over-medicalization) make it landmark evidence. Editors value 'definitive negatives' as much as positives in high-frequency clinical scenarios.
In light of the PRISM trial, how should current NICE or ACOG recommendations be adjusted regarding the use of progesterone in threatened miscarriage, specifically for women with a history of one or more losses?
Key Response
Following PRISM, NICE updated guideline NG126 to recommend 400mg micronized progesterone BID for women with vaginal bleeding and a history of at least one previous miscarriage. This represents a nuanced shift from treating 'everyone' or 'no one' to a 'targeted' evidence-based approach based on obstetric history.
Clinical Landscape
Noteworthy Related Trials
PROMISE Trial
Tested
Micronized vaginal progesterone
Population
Women with unexplained recurrent miscarriage
Comparator
Placebo
Endpoint
Live birth rate
PICTURE Trial
Tested
Vaginal progesterone
Population
Women with early pregnancy bleeding and a history of recurrent miscarriage
Comparator
Placebo
Endpoint
Live birth rate
OPPTIMUM Trial
Tested
Vaginal progesterone
Population
Women at high risk of preterm birth
Comparator
Placebo
Endpoint
Neurodevelopmental outcome at 2 years of age
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis